Innovative clinical trial design for pediatric therapeutics

Expert Review of Clinical Pharmacology

Volumn 4, Issue 5, 2011, Pages 643-652

  Laughon, Matthew M ^a   Benjamin Jr , Daniel K ^b,c   Capparelli, Edmund V ^d   Kearns, Gregory L ^e   Berezny, Katherine ^c   Paul, Ian M ^f   Wade, Kelly ^g   Barrett, Jeff ^f   Smith, Phillip Brian ^b,c   Cohen Wolkowiez, Michael ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHILDREN S MERCY HOSPITAL   (United States)

^f PENN STATE COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

clinical trial simulation; opportunistic study; pediatrics; pharmacodynamics; pharmacokinetics; pharmacometrics; therapeutics

Indexed keywords

ACICLOVIR; AMINOPHYLLINE; AMPICILLIN; BERACTANT; CAFFEINE CITRATE; CEFALEXIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; DAPTOMYCIN; DOPAMINE; FLUCONAZOLE; FUROSEMIDE; GENTAMICIN; MEROPENEM; METOCLOPRAMIDE; METRONIDAZOLE; MICAFUNGIN; MIDAZOLAM; MORPHINE; OSELTAMIVIR; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PROPOFOL; UNINDEXED DRUG; VALGANCICLOVIR; VANCOMYCIN;

CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG LABELING; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; GESTATIONAL AGE; HUMAN; OBESITY; OFF LABEL DRUG USE; PEDIATRICS; PHARMACODYNAMICS; PHARMACOGENOMICS; PREMATURITY; REVIEW;

AGE FACTORS; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; THERAPIES, INVESTIGATIONAL;

EID: 80052765511     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.43     Document Type: Review

References (89)

1. Shirkey HC. Therapeutic orphans - everybody's business. Ann. Pharmacother. 40(6), 1174 (2006).
2. Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin. Drug Saf. 3(2), 81-83 (2004). (Pubitemid 38765189)
3. Roberts R, Rodriguez W, Murphy D et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 290(7), 905-911 (2003). (Pubitemid 37430462)
4. Turner S, Nunn AJ, Fielding K et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 88(9), 965-968 (1999). (Pubitemid 29448261)
5. Avenel S, Bomkratz A, Dassieu G et al. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch. Pediatr. 7(2), 143-147 (2000). (Pubitemid 30091004)
6. O'Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 110(5), e52 (2002).
7. T Jong GW, Vulto AG, de Hoog M et al. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 108(5), 1089-1093 (2001). (Pubitemid 33021180)
8. Rodriguez W, Selen A, Avant D et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 121(3), 530-539 (2008).
9. Smith PB, Benjamin DK Jr, Murphy MD et al. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics 122(3), E628-E633 (2008).
10. Benjamin DK Jr, Smith PB, Sun MJ et al. Safety and transparency of pediatric drug trials. Arch. Pediatr. Adolesc. Med. 163(12), 1080-1086 (2009).
11. Benjamin DK Jr, Smith PB, Murphy MD et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 296(10), 1266-1273 (2006). (Pubitemid 44394898)
12. Wade KC, Wu D, Kaufman DA et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob. Agents Chemother. 52(11), 4043-4049 (2008).
13. Cohen-Wolkowiez M, Benjamin DK Jr, Steinbach WJ et al. Anidulafungin: a new echinocandin for the treatment of fungal infections. Drugs Today (Barc.) 42(8), 533-544 (2006). (Pubitemid 44504261)
14. Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 51(10), 3714-3719 (2007). (Pubitemid 47519363)
15. Benjamin DK Jr, Smith P, Arrieta A et al. Safety and pharmacokinetics of repeat-dose micafungin in neonates. Presented at: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 25-28 October 2008.
16. Holford N, Dosing in children. Clin. Pharmacol. Ther. 87(3), 367-370 (2010).
17. Acosta EP, Jester P, Gal P et al. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202(4), 563-566 (2010).
18. Andersen DH, Blanc WA, Crozier DN et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 18(4), 614-625 (1956).
19. Stewart DJ. The effects of tetracyclines upon the dentition. Br. J. Dermatol. 76, 374-378 (1964).
20. Burns LE, Hodgman JE, Cass AB, Fatal circulatory collapse in premature infants receiving chloramphenicol. N. Engl. J. Med. 261, 1318-1321 (1959).
21. YehTF, Lin YJ, Huang CC et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 101(5), E7 (1998).
22. Aranda JV, Clarkson S, Collinge JM. Changing pattern of drug utilization in a neonatal intensive care unit. Am. J. Perinatol. 1(1), 28-30 (1983). (Pubitemid 14152817)
23. Du W, Warrier I, Tutag Lehr V et al. Changing patterns of drug utilization in a neonatal intensive care population. Am. J. Perinatol. 23(5), 279-285 (2006).
24. Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003). (Pubitemid 37122329)
25. Burtin P, Jacqz-Aigrain E, Girard P et al. Population pharmacokinetics of midazolam in neonates. Clin. Pharmacol. Ther. 56(6 Pt 1), 615-625 (1994). (Pubitemid 124006569)
26. Anand KJ, Anderson BJ, Holford NH et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br. J. Anaesth. 101(5), 680-689 (2008).
27. Pacifici GM, Labatia J, Mulla H et al. Clinical pharmacokinetics of penicillins in the neonate: a review of the literature. Eur. J. Clin. Pharmacol. 65(2), 191-198 (2009).
28. Allegaert K, Peeters MY, Verbesselt R et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br. J. Anaesth. 99(6), 864-870 (2007). (Pubitemid 351773375)
29. Peeters MY, Allegaert K, Blussé van Oud-Alblas HJ et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin. Pharmacokinet. 49(4), 269-275 (2010).
30. Fischer S, Bohn D, Rycus P et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: analysis of the Extracorporeal Life Support Organization (ELSO) registry. J. Heart Lung Transplant. 26(5), 472-477 (2007). (Pubitemid 46602004)
31. Meyer DM, Jessen ME. Results of extracorporeal membrane oxygenation in children with sepsis. The Extracorporeal Life Support Organization. Ann. Thorac. Surg. 63(3), 756-761 (1997). (Pubitemid 27128694)
32. Green TP, Timmons OD, Fackler JC et al. The impact of extracorporeal membrane oxygenation on survival in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. Crit. Care Med. 24(2), 323-329 (1996). (Pubitemid 26065343)
33. Lequier L, Extracorporeal life support in pediatric and neonatal critical care: a review. J. Intensive Care Med. 19(5), 243-258 (2004).
34. Frenckner B, Radell P. Respiratory failure and extracorporeal membrane oxygenation. Semin. Pediatr. Surg. 17(1), 34-41 (2008). (Pubitemid 350297997)
35. Rajagopal SK, Almond CS, Laussen PC et al. Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the Extracorporeal Life Support Organization registry. Crit. Care Med. 38(2), 382-387 (2010).
36. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin. Pharmacokinet. 42(5), 403-417 (2003). (Pubitemid 36649036)
37. Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob. Agents Chemother. 33(6), 817-819 (1989). (Pubitemid 19146566)
38. Cohen P, Collart L, Prober CG et al. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr. Infect. Dis. J. 9(8), 562-566 (1990). (Pubitemid 20260479)
39. Dodge WF, Jelliffe RW, Zwischenberger JB et al. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther. Drug Monit. 16(6), 552-559 (1994). (Pubitemid 24376713)
40. Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 12(1), 28-32 (1992).
41. Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans. 37(1), 16-18 (1991).
42. Hoie EB, Swigart SA, Leuschen MP et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin. Pharm. 9(9), 711-715 (1990). (Pubitemid 20323745)
43. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob. Agents Chemother. 40(5), 1139-1142 (1996). (Pubitemid 26136023)
44. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 18(5), 1082-1086 (1998). (Pubitemid 28439994)
45. Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion 20(6), 309-315 (2005). (Pubitemid 41824359)
46. Dagan O, Klein J, Bohn D et al. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit. Care Med. 22(7), 1099-1101 (1994). (Pubitemid 24219414)
47. Mehta NM, Halwick DR, Dodson BL et al. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 33(6), 1018-1024 (2007). (Pubitemid 46835404)
48. Mulla H, Lawson G, von Anrep C et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion 15(1), 21-26 (2000). (Pubitemid 30064112)
49. Drug Therapies in Neonates and Children During Extracorporeal Membrane Oxygenation (ECMO); Keep Your Eyes Open. Wildschut E (Ed.).Erasmus MC, Rotterdam, The Netherlands (2010).
50. Peters JW, Anderson BJ, Simons SH et al. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med. 31(2), 257-263 (2005). (Pubitemid 40362275)
51. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 303(3), 242-249 (2010).
52. Poggesi I, Benedetti MS, Whomsley R et al. Pharmacokinetics in special populations. Drug Metab. Rev. 41(3), 422-454 (2009).
53. Srinivasan V, Nadkarni VM, Helfaer MA et al. Childhood obesity and survival after in-hospital pediatric cardiopulmonary resuscitation. Pediatrics 125(3), e481-e488 (2010).
54. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49(2), 71-87 (2010).
55. Sammons H. Ethical issues of clinical trials in children: a European perspective. Arch. Dis. Child 94(6), 474-477 (2009).
56. de Hoog M, Schoemaker RC, Mouton JW et al. Vancomycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 67(4), 360-367 (2000). (Pubitemid 30246811)
57. Garcia B, Barcia E, Perez F et al. Population pharmacokinetics of gentamicin in premature newborns. J. Antimicrob. Chemother. 58(2), 372-379 (2006). (Pubitemid 44294950)
58. Bouvier d'Yvoire M, Prieto P, Blaauboer BJ et al. Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern. Lab. Anim. 35(6) 661-671 (2007). (Pubitemid 351169738)
59. Bois FY, Jamei M, Clewell HJ. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278(3), 256-267 (2010).
60. Bradley JS, Sauberan JB, Ambrose PG et al. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr. Infect. Dis. J. 27(9), 794-799 (2008).
61. Capparelli E, Hochwald C, Rasmussen M et al. Population pharmacokinetics of cefepime in the neonate. Antimicrob. Agents Chemother. 49(7), 2760-2766 (2005). (Pubitemid 40917589)
62. Pullen J, Stolk LM, Nieman FH et al. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther. Drug Monit. 28(2), 226-231 (2006). (Pubitemid 44314953)
63. Benjamin DK Jr, Smith PB, Arrieta A et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin. Pharmacol. Ther. 87(1), 93-99 (2010).
64. Smith PB, Walsh TJ, Hope W et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr. Infect Dis. J. 28(5), 412-415 (2009).
65. Acosta EP, Brundage RC, King JR et al.; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin. Pharmacol. Ther. 81(6), 867-872 (2007). (Pubitemid 46788295)
66. Ahsman MJ, Wildschut ED, Tibboel D et al. Microanalysis of b-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. Antimicrob. Agents Chemother. 53(1), 75-80 (2009).
67. Jung BH, Rezk NL, Bridges AS et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 21(10), 1095-1104 (2007). (Pubitemid 47490320)
68. Denooz R, Charlier C. Simultaneous determination of five b-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 864(1-2), 161-167 (2008).
69. Holt DE, de Louvois J, Hurley R et al. A high performance liquid chromatography system for the simultaneous assay of some antibiotics commonly found in combination in clinical samples. J. Antimicrob. Chemother. 26(1), 107-115 (1990). (Pubitemid 20263703)
70. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal. Chem. 81(4), 1557-1563 (2009).
71. Cheung CY, van der Heijden J, Hoogtanders K et al. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl. Int. 21(2), 140-145 (2008).
72. Allanson AL, Cotton MM, Tettey JN et al. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J. Pharm. Biomed. Anal. 44(4), 963-969 (2007). (Pubitemid 47096856)
73. Hibberd SG, Alveyn C, Coombes EJ et al. Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. Br. J. Clin. Pharmacol. 22(3), 337-341 (1986). (Pubitemid 17170724)
74. Suyagh MF, Iheagwaram G, Kole PL et al. Development and validation of a dried blood spot-HPLC assay for the determination of metronidazole in neonatal whole blood samples. Anal. Bioanal. Chem. 397(2), 687-693 (2010).
75. Suyagh M, Collier PS, Millership JS et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 127(2), e367-e374 (2011).
76. Leeder JS, Kearns GL, Spielberg SP et al. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J. Clin. Pharmacol. 50(12), 1377-1387 (2010).
77. Kearns GL, Andersson T, James LP et al. Omeprazole disposition in children following single-dose administration. J. Clin. Pharmacol. 43(8), 840-848 (2003). (Pubitemid 36886104)
78. Kearns GL, Blumer J, Schexnayder S et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J. Clin. Pharmacol. 48(11), 1356-1365 (2008).
79. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19.*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab. Dispos. 38(6), 894-897 (2010).
80. Capparelli EV, Englund JA, Connor JD et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J. Clin. Pharmacol. 43(2), 133-140 (2003). (Pubitemid 36125939)
81. Wade KC, Benjamin DK Jr, Kaufman DA et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr. Infect. Dis. J. 28(8), 717-723 (2009).
82. Barrett J. Modeling and Simulation. In: Pediatric Research and Development, in Clinical Trial Simulations: Applications & Trends. Kimko H, Peck C (Eds).Springer Science + Business Media, NY, USA (2011).
83. Huisman-de Boer JJ, van den Anker JN, Vogel M et al. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrob. Agents Chemother. 39(2), 431-434 (1995).
84. Peltola H, Ukkonen P, Saxen H et al. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. Pediatrics 101(4 Pt 1), 658-662 (1998). (Pubitemid 28180152)
85. Abdel-Rahman SM, Benziger DP, Jacobs RF et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr. Infect. Dis. J. 27(4), 330-334 (2008). (Pubitemid 351483068)
86. Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. J. Pediatr. Surg. 23(3), 263-265 (1988). (Pubitemid 18086368)
87. Smith P, Walsh T, Hope W et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Presented at: Annual Pediatric Academic Societies Meeting, 2008. Honolulu, HI, USA, 2-6 May 2008.
88. Clark RH, Bloom BH, Spitzer AR et al. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 117(6), 1979-1987 (2006). (Pubitemid 46071242)
89. Husain A, Loehle JA, Hein DW. Clinical pharmacogenetics in pediatric patients. Pharmacogenomics 8(10), 1403-1411 (2007). (Pubitemid 350167103)